Reneo Pharmaceuticals Inc reports results for the quarter ended in September - Earnings Summary

Onkure Therapeutics

09/11/2022 12:00

* Reneo Pharmaceuticals Inc  RPHM.OQ  reported a quarterly
adjusted loss of 53 cents​​ per share for the quarter ended in
September. The mean expectation of six analysts for the quarter
was for a loss of 57 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Reneo Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 53 cents​.
    * The mean earnings estimate of analysts had risen by
about 1.1%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Reneo Pharmaceuticals Inc shares had fallen by 9.9% this
quarter and lost 64.7% so far this year.
    * The company reported a quarterly loss of $13.2 million.
    * Wall Street's median 12-month price target for Reneo
Pharmaceuticals Inc is $26.50 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 6 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
9 at 12:00 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      -0.57          -0.53          Beat
 Jun. 30 2022      -0.58          -0.50          Beat
 Mar. 31 2022      -0.54          -0.53          Beat
 Dec. 31 2021      -0.57          -0.43          Beat